Surgical Science delivered a strong Q2, with sales 6% above our expectations and an EBIT margin of 13% versus our 9% estimate. We are also encouraged by the reassessment of the potential revenue impact from the non-materialised Intuitive MoU. We expect the share to react positively to the report today by 5–10%.
LÄS MER
